NEWS

MIMETOGEN PHARMACEUTICALS ENTERS INTO LICENSING AGREEMENT WITH ALLERGAN

05 Nov 2015

Aligo is pleased to highlight the signature of an agreement between Mimetogen and Allergan. MSBi Valorisation, now an integral part of Aligo, helped fuel Mimetogen’s success, through the financing and guidance services provided at the early stage of the company’s development. The benefits generated for MSBi Valorisation, Aligo and McGill University are significant and the results demonstrate the relevance of MSBiV / Aligo business model. We congratulate Mr. Garth Cumberlidge, Mimetogen’s CEO and his team, as well as Dr. Uri Saragovi, the principal researcher whose work led to the discovery of the product developed by Mimetogen, for their accomplishments.

Mimetogen Pharmaceuticals Announces Topline Results of Its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome

25 Sep 2014

Mimetogen Pharmaceuticals Inc. (“Mimetogen”) today announced positive top line data from its second clinical study (Study Designation MIM-725) with MIM-D3, its lead drug for the treatment of dry eye syndrome. The trial demonstrated significant improvements in both signs and symptoms with 1% MIM-D3 versus placebo, together with excellent safety, comfort and tolerability profiles.

OUR PARTNER INSTITUTIONS

Warning
Ok
CancelLogin